Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact

Gon, Yasufumi; Morishima, Toshitaka; Kawano, Tomohiro; Okazaki, Shuhei; Todo, Kenichi; Sasaki, Tsutomu; Mochizuki, Hideki; Miyashiro, Isao

doi:https://doi.org/10.1016/j.jaccao.2024.01.006

Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact

Gon, Yasufumi; Morishima, Toshitaka; Kawano, Tomohiro et al.

JACC: CardioOncology, 2024, 6(2), 283-297

アクセス数:1,024件（2025-09-01 14:49 集計）

固定URL: https://hdl.handle.net/11094/95636

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
JACC_CardioOncology_6_2_283	pdf	なし	2.95 MB	56	2024.05.17

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact
著者	NRID 1000070751311 1000070751311 researchmap permalink y-gon y-gon Scopus Author ID 56565092900 56565092900 著者名 Gon, Yasufumi
	NRID 1000010728893 1000010728893 researchmap permalink morishima morishima 著者名 Morishima, Toshitaka
	著者名 Kawano, Tomohiro
	NRID 1000060623072 1000060623072 researchmap permalink s-okazaki s-okazaki Scopus Author ID 16417354000 16417354000 著者名 Okazaki, Shuhei
	NRID 1000040403068 1000040403068 researchmap permalink kenichitodo kenichitodo Scopus Author ID 22954718500 22954718500 著者名 Todo, Kenichi
	NRID 1000020534879 1000020534879 ORCID 0000-0001-8726-978X 0000-0001-8726-978X researchmap permalink tsutomusasaki1111 tsutomusasaki1111 Scopus Author ID 7407394272 7407394272 著者名 Sasaki, Tsutomu
	NRID 1000090230044 1000090230044 ORCID 0000-0002-0874-7542 0000-0002-0874-7542 researchmap permalink read0207787 read0207787 Scopus Author ID 7202006099 7202006099 著者名 Mochizuki, Hideki
	NRID 1000080501824 1000080501824 著者名 Miyashiro, Isao
キーワード等	advanced age
	antithrombotic therapy
	hematologic malignancies
	Kaplan-Meier curve
	risk
内容	Gon Y., Morishima T., Kawano T., et al. Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact. JACC: CardioOncology 6, 283 (2024); https://doi.org/10.1016/j.jaccao.2024.01.006.
抄録	Background: Thromboembolism is a significant complication for patients with cancer, leading to treatment interruptions and poor outcomes. Objectives: The aim of this study was to investigate the incidence of arterial thromboembolism (ATE) within cancer populations, identify the predictors of ATE, and determine its survival impact. Methods: A retrospective multicenter study was performed using data from the Osaka Cancer Registry linked with administrative data from 2010 to 2015. Patients were monitored for 5 years after cancer diagnosis, and ATE incidence was calculated with death as a competing risk. Fine and Gray competing risk regression models and Cox proportional hazards models were used to evaluate the predictors of ATE and the survival impact. Restricted mean survival time (RMST) was used to assess whether antithrombotic therapy after ATE contributed to improved survival. Results: The cohort comprised 97,448 patients with cancer (42.3% women, median age 70 years). ATE incidence displayed an annual increase, peaking 1 year after cancer diagnosis (1-, 2-, 3-, 4-, and 5-year cumulative incidences were 1.29%, 1.77%, 2.05%, 2.22%, and 2.32%, respectively). Male sex, advanced age, advanced cancer stage, and hematologic malignancies correlated with a high risk for ATE. Patients with ATE had a 2-fold increased risk for mortality compared with those without ATE. The 90-day and 1-year RMST differences for those on antithrombotic therapy were 13.3 days (95% CI: 10.4-16.2 days; P < 0.001) and 57.8 days (95% CI: 43.1-72.5 days; P < 0.001), favoring the antithrombotic therapy group. The RMST differences varied by cancer stage. Conclusions: The risk for ATE varies according to sex, age, and cancer progression and type. Antithrombotic therapy after ATE is associated with improved survival among patients with cancer.
出版者	Elsevier Inc.
収録物名	JACC: CardioOncology
巻(号)	6(2)
ページ	283-297
刊行年月	2024-04-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/95636
eISSN	26660873
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.jaccao.2024.01.006
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	JACC: CardioOncology. 2024, 6(2), p. 283-297
DC.title	Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact
DC.creator	Gon, Yasufumi
	Morishima, Toshitaka
	Kawano, Tomohiro
	Okazaki, Shuhei
	Todo, Kenichi
	Sasaki, Tsutomu
	Mochizuki, Hideki
	Miyashiro, Isao
DC.publisher	Elsevier Inc.
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-04-01
DC.identifier	https://doi.org/10.1016/j.jaccao.2024.01.006
DC.subject	advanced age
	antithrombotic therapy
	hematologic malignancies
	Kaplan-Meier curve
	risk
DC.description	Gon Y., Morishima T., Kawano T., et al. Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact. JACC: CardioOncology 6, 283 (2024); https://doi.org/10.1016/j.jaccao.2024.01.006.
DCTERMS.abstract	Background: Thromboembolism is a significant complication for patients with cancer, leading to treatment interruptions and poor outcomes. Objectives: The aim of this study was to investigate the incidence of arterial thromboembolism (ATE) within cancer populations, identify the predictors of ATE, and determine its survival impact. Methods: A retrospective multicenter study was performed using data from the Osaka Cancer Registry linked with administrative data from 2010 to 2015. Patients were monitored for 5 years after cancer diagnosis, and ATE incidence was calculated with death as a competing risk. Fine and Gray competing risk regression models and Cox proportional hazards models were used to evaluate the predictors of ATE and the survival impact. Restricted mean survival time (RMST) was used to assess whether antithrombotic therapy after ATE contributed to improved survival. Results: The cohort comprised 97,448 patients with cancer (42.3% women, median age 70 years). ATE incidence displayed an annual increase, peaking 1 year after cancer diagnosis (1-, 2-, 3-, 4-, and 5-year cumulative incidences were 1.29%, 1.77%, 2.05%, 2.22%, and 2.32%, respectively). Male sex, advanced age, advanced cancer stage, and hematologic malignancies correlated with a high risk for ATE. Patients with ATE had a 2-fold increased risk for mortality compared with those without ATE. The 90-day and 1-year RMST differences for those on antithrombotic therapy were 13.3 days (95% CI: 10.4-16.2 days; P < 0.001) and 57.8 days (95% CI: 43.1-72.5 days; P < 0.001), favoring the antithrombotic therapy group. The RMST differences varied by cancer stage. Conclusions: The risk for ATE varies according to sex, age, and cancer progression and type. Antithrombotic therapy after ATE is associated with improved survival among patients with cancer.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	95636
citation_title	Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact
citation_author	Gon, Yasufumi
	Morishima, Toshitaka
	Kawano, Tomohiro
	Okazaki, Shuhei
	Todo, Kenichi
	Sasaki, Tsutomu
	Mochizuki, Hideki
	Miyashiro, Isao
citation_publisher	Elsevier Inc.
citation_language	英語
citation_date	2024-04-01
citation_journal_title	JACC: CardioOncology
citation_volume	6
citation_issue	2
citation_firstpage	283
citation_lastpage	297
citation_doi	https://doi.org/10.1016/j.jaccao.2024.01.006
citation_public_url	https://hdl.handle.net/11094/95636

Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact

閲覧可能ファイル

論文情報

論文詳細を表示